Remission maintenance therapy in acute myelogenous leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Efficacy of maintenance chemotherapy for acute myelogenous leukemia (AML) remained inconclusive.
• Induction chemotherapy achieves complete remission in AML patients.

Purpose of the Study:

• To evaluate the efficacy of maintenance chemotherapy in prolonging remission duration in adult AML patients.
• To assess the safety and impact on reinduction therapy of maintenance chemotherapy.

Main Methods:

• Randomized controlled trial involving 26 adult AML patients in complete remission.
• Patients received either monthly maintenance chemotherapy (cytarabine and 6-thioguanine) or no maintenance therapy.
• Remission duration, toxicity, and reinduction rates were monitored.

Main Results:

• Median remission duration was significantly longer in the maintenance group (10.3 months) versus the control group (6.7 months) (p<.05).
• 46% of maintained patients had remissions >11 months, compared to 0% in the unmaintained group.
• No significant drug-induced toxicity was observed, and reinduction rates were identical (50% complete remission).

Conclusions:

• Maintenance chemotherapy with cytarabine and 6-thioguanine appears beneficial for prolonging remission duration in AML.
• The treatment regimen is well-tolerated and does not compromise subsequent remission induction.
• Maintenance therapy did not show benefit in patients with splenomegaly at diagnosis.